Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Non-steroidal anti-inflammatory drugs Stories

2013-05-07 08:32:21

MADISON, Tenn., May 7, 2013 /PRNewswire/ -- Since 2007, the total cost of diabetes treatment in the United States has risen from $174 billion to $245 billion. Nearly 26 million adults and children currently live with the disease. Per capita medical expenditures now total $7,900. Chronic pain and neuropathy necessitate a steady regimen of prescription pain relief medications, which is one of the more significant factors contributing these numbers. These findings are the result of a...

2013-04-22 11:27:41

Risk increases with dose; unrecognized problem, doctors warn Many competitors try to prevent pain interfering with their performance by taking painkillers that are readily available in pharmacies and supermarkets, say the authors. And in a bid to find out what impact these common drugs might have, the authors quizzed participants in the 2010 Bonn Marathon/Half-Marathon about their use of medication and any symptoms they had during and/or after the race. In all, just under 4000 (56%)...

2013-04-18 08:30:50

Imprimis Pharmaceuticals, Inc., Concluded its April 15th, 2013 Meeting with the FDA in Washington, D.C., and Reviewed the Company's Development Program for its Lead Phase III Drug Candidate, Impracor(TM) SOLANA BEACH, Calif., April 18, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced that on April 15(th), 2013, the Company attended its Type C meeting with the U.S. Food and Drug Administration (FDA) which included the review of the development plan for...

2013-04-08 08:29:56

New Once-Daily NSAID Indicated for Treatment of Postoperative Inflammation and Reduction of Ocular Pain Following Cataract Surgery MADISON, N.J., April 8, 2013 /PRNewswire/ -- Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for PROLENSA(TM) (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory...

Heart Attack Prevention With Aspirin Still Popular, Despite Lack Of Beneficial Evidence
2013-03-20 10:30:41

redOrbit Staff & Wire Reports - Your Universe Online Using aspirin for cardiovascular health remains a popular preventative medicine regimen for many people, even though recent studies have suggested that the popular pain killer might not be as beneficial as previously believed, according to new research published in the journal Canadian Family Physician. Study authors Olga Szafran and Mike Kolber of the University of Alberta´s Department of Family Medicine polled patients over...

2013-03-05 08:28:30

MISSISSAUGA, ON, March 5, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV), has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully...

2013-02-28 08:30:48

Safe alternative pain relief offers immediate healthcare solutions and long-term savings MADISON, Tenn., Feb. 28, 2013 /PRNewswire/ -- A recently completed study finds that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) pose costly dangers for senior citizens. "Actuarial Cost Profile of Pain Management Using Prescription NSAIDs" documents the fast-growing financial toll linked to NSAID toxicity and side effects. Vireo Systems, Inc., which specializes in safe, effective pain relief...

2013-02-26 16:27:11

NEWARK, Calif., Feb. 26, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Cowen and Company 33rd Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston. The presentation at the Cowen conference is scheduled for 10:00 am EST (7:00 am PST) on Tuesday, March 5, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording...

2013-02-25 04:22:14

GREENWOOD VILLAGE, Colo., Feb. 25, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced today that it's Phase III clinical study of Ampion(TM) for the treatment for osteoarthritis of the knee will include a dose-escalation run-in( )study as recommended by the FDA. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, explained "In the Australian trial, a single 4 ml dose provided promising results...

2013-02-19 08:32:52

SOLANA BEACH, Calif., Feb. 19, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY:NASDAQ) today announced the completion of a clinical study of Impracor(TM), a topical analgesic cream that delivers a therapeutic dose of the pain-relieving, anti-inflammatory drug ketoprofen. The study measured the amount of ketoprofen found in the bloodstream following topical application of two different doses of the anti-inflammatory cream under different conditions, including normal activities, heat...